Tag: ISC 2023
CHI Memorial announces participation in “milestone” stroke study with novel ultrasound...
The Catholic Health Initiatives (CHI) Memorial Stroke and Neuroscience Center has announced its participation in the national research study, BUBL, stating that it was...
Uric acid-based neuroprotective agent demonstrates promise in large animal study
The opening day of the 2023 International Stroke Conference (ISC; 8–10 February, Dallas, USA) saw the presentation of findings from an animal-model study that...
Randomised trial fails to show benefit with bypass surgery in symptomatic...
The initial findings from a recent randomised controlled trial (RCT) do not support the addition of extracranial to intracranial (EC-IC) bypass surgery to the...
ANGEL-ASPECT data bolster evidence for thrombectomy in large infarct core stroke
A randomised trial has found mechanical thrombectomy procedures performed within 24 hours of symptom onset to be more effective than standard medical care in...
Dual antiplatelet therapy comparable to thrombolysis in minor, non-disabling ischaemic stroke
Among Chinese patients with minor, non-disabling stroke presenting <4.5 hours from symptom onset, dual antiplatelet therapy (DAPT) has been found to be non-inferior to...
Celery seed derivative shows promise as neuroprotectant in acute ischaemic stroke
Ischaemic stroke patients treated with a clot-busting medication and/or mechanical thrombectomy who also received butylphthalide—a novel medication initially compounded from celery seed—experienced milder neurological...
Chinese TRACE II trial deems tenecteplase non-inferior to alteplase in ischaemic...
New data on intravenous tenecteplase indicate that it can achieve comparable efficacy and safety to alteplase in treating stroke—and, as such, may be used...
New smartphone app may help to identify stroke symptoms as they...
A new smartphone application called FAST.AI (Neuronics Medical) may help people who are having a stroke—or their family and caregivers—to recognise common stroke symptoms in real...
Wallaby/Phenox announces presentation of PROST trial data at ISC 2023
Phenox, a Wallaby Medical company, has today announced the presentation of the primary results of the PROST (Preset for occlusive stroke treatment) randomised clinical...
SELECT2 results support thrombectomy use in stroke patients with large infarct-core...
An international clinical study has found that patients experiencing a ‘large’ stroke—characterised by a greater infarct-core volume on imaging—had a dramatically better recovery after...
ISC 2023 sees presentation of positive data on new stroke drugs...
New data pointing to the possible advantages held by several drug products in treating acute ischaemic stroke were delivered at the recent International Stroke...
Blood pressure lowering after EVT “should be customised” owing to safety...
The administration of medications to lower systolic blood pressure in acute ischaemic stroke patients who have undergone a successful mechanical thrombectomy procedure—also known as...
Hyperfine announces new data on portable MRI in post-thrombectomy stroke patients
Hyperfine has announced the presentation of new stroke patient follow-up data regarding the use of the Swoop system—which it claims is the world’s first US...
Two cardiovascular medicines found to be “well-tolerated” in small vessel stroke
A study of two widely used cardiovascular medications—cilostazol and isosorbide mononitrate—in more than 350 patients has confirmed that both were well-tolerated and safe for...
Continuous monitoring detects atrial fibrillation in 20% of atherosclerotic stroke survivors
In a study presented yesterday at the International Stroke Conference (ISC; 8–10 February, Dallas, USA), irregular heart rhythms were detected in roughly one in...
Real-world study demonstrates “highly clinically important” time saving with Viz platform
Viz.ai and TeleSpecialists have announced new data presented at the 2023 International Stroke Conference (ISC; 8–10 February, Dallas, USA) from the VALIDATE study, which...
Neuroprotective agent linked to reduced death and disability in ischaemic stroke...
ApTOLL, a neuroprotectant medication intended to shield the brain from tissue damage, has been linked to reduced death and disability when used alongside standard...
Basking Biosciences to present trial data on novel reversible thrombolytic agent...
Basking Biosciences has announced that it will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate—a reversible thrombolytic...
